PRESS RELEASES

The merger of Cerba Research and Viroclinics-DDL

The merger of Cerba Research and Viroclinics-DDL

After the acquisition of Viroclinics-DDL by the group Cerba Healthcare, we are delighted to announce that Cerba Research, the group’s global clinical trial central and speciality laboratory services division, has now merged with Viroclinics-DDL, a fast-growing global specialist virology and immunology contract research organisation (CRO).

Viroclinics-DDL and CEPI strengthen partnership with the production of Omicron SARS-CoV-2 variant for distribution in the CEPI COVID-19 Vaccine Testing Network

Viroclinics-DDL and CEPI strengthen partnership with the production of Omicron SARS-CoV-2 variant for distribution in the CEPI COVID-19 Vaccine Testing Network

Today, Viroclinics-DDL, a global Contract Research Organization supporting clinical and preclinical studies for drug and vaccine development and CEPI, the Coalition for Epidemic Preparedness Innovations, signed an agreement which allows Viroclinics-DDL to produce and distribute laboratory stocks of the Omicron SARS-CoV-2 variant for use in CEPI’s centralised COVID-19 vaccine testing network. The produced Omicron SARS-COV-2 variant will be used for the performance of laboratory assays, assessing the neutralizing potential of COVID-19 vaccines against the new variant.

↓